NCT02843074

Disease Type: Hematology
Status: Open

Trial Information

Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact: